Interpace Biosciences Completes Sale of Its Pharma Services Business to Flagship Biosciences, Inc. Aug 31, 2022
Interpace Biosciences Announces Second Quarter 2022 Financial and Business Results and New Clinical Validation Data; Diagnostic Accuracy Significantly Improved Aug 15, 2022
Miroculus to Optimize Automated Next Generation Sequencing Library Preparation with Interpace Diagnostics and Twist Bioscience May 11, 2022
Interpace Biosciences Announces Full Year and Fourth Quarter 2021 Financial and Business Results Mar 31, 2022
Interpace Biosciences Announces Update of Previously Announced CMS Billing Policy Impacting its Thyroid Tests Feb 22, 2022
Interpace Biosciences Terminates Rights Offering Announces Change in CMS Medicare Reimbursement of its Thyroid Tests Jan 28, 2022
Interpace Biosciences Announces Commencement of Fully Back-Stopped $30 Million Rights Offering Jan 12, 2022
Interpace Biosciences Announces Record Date for Proposed Fully Back-Stopped $30 Million Rights Offering Jan 3, 2022
